Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunotherapy

Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies

Nature Reviews Clinical Oncology volume 14, pages 333–334 (2017)Cite this article

Subjects

Adoptive cellular therapy (ACT) is now considered a bona fide treatment modality within the evolving field of anticancer immunotherapy. Great advances have enabled the adoptive transfer of tumour-selective lymphocytes for the treatment of a variety of malignancies. Unfortunately, this selectivity has led to the emergence of antigen-loss variants. New strategies need to be employed to minimize the incidence of this phenomenon, enabling the full potential of ACT to be realized.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255–2262 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Evans, A. G. et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205–209 (2015).

    Article  CAS  PubMed  Google Scholar 

  4. Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406–2410 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rayes, A., McMasters, R. L. & O'Brien, M. M. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer 63, 1113–1115 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01701674 (2016).

  8. Cha, E. et al. Improved survival with T cell clonotype stability sfter anti-CTLA-4 treatment in cancer patients. Sci. Transl Med. 6, 238ra70 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ruella, M. et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814–3826 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the following for financial support: The Leukemia & Lymphoma society; The U.S. National Institutes of Health Grants (R01CA138738-05, PO1CA059350, PO1CA190174-01); The Annual Terry Fox Run for Cancer Research (New York, NY) organized by the Canada Club of New York; Kate's Team; Carson Family Charitable Trust; William Lawrence and Blanche Hughes Foundation; Emerald Foundation; the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center (Innovations in the structures, functions and targets of monoclonal antibody-based drugs for cancer).

Author information

Authors and Affiliations

  1. Anthony F. Daniyan and Renier J. Brentjens are at the Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.,

    Anthony F. Daniyan & Renier J. Brentjens

Authors
  1. Anthony F. Daniyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renier J. Brentjens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renier J. Brentjens.

Ethics declarations

Competing interests

R.J.B. is a scientific co-founder of, reports receiving a commercial research grant from, has ownership interest (including patents) in, and is a consultant/advisory board member of JUNO Therapeutics. A.F.D. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daniyan, A., Brentjens, R. Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies. Nat Rev Clin Oncol 14, 333–334 (2017). https://doi.org/10.1038/nrclinonc.2017.49

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.49

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing